SENTRY study – investigating the safety and efficacy of the combination of selinexor plus ruxolitinib in myelofibrosis

Icahn School of Medicine at Mount Sinai shared on X:

“The SENTRY study, led by Dr. John Mascarenhas, is investigating the safety and efficacy of the combination of selinexor (Xpovio) plus ruxolitinib (Jakafi) for the treatment of patients with JAK inhibitor treatment-naive myelofibrosis.”